Custom protein production at quantity: specifying a batch, the release testing it needs, and securing repeat supply at the same quality

Production is the stage after a process exists: the question is no longer whether the protein can be made but how to get a defined quantity at a defined quality, repeatedly. That shifts every decision toward specification, release testing and comparability between lots, and away from the development questions that dominated earlier. This page covers how to commission a production batch and how to make the second one match the first.

the FDA cGMP rule that applies once material is destined for a drug product
Part 211
the ICH guideline on deriving and characterising cell substrates
Q5D
good laboratory practice for nonclinical studies, 21 CFR
Part 58

Figures in this panel are the rules a contract biologics service is bought and audited against, named from the regulations and guidelines themselves and linked in the sources below. They are identifiers, not prices: BioBricks publishes verified prices for synthesis services only, and does not imply a services index it has not measured.

Commissioning a batch

  1. Size the batch from consumption and stability. Order what will be used inside the material's demonstrated stability period plus a reserve, not the largest batch the unit price favours. Protein that degrades in storage is more expensive than a second batch, and stability is a property of your formulation rather than a general rule.
  2. Write a release specification. Identity, purity by a stated method, concentration by a stated method, activity where relevant, aggregate, endotoxin and appearance, each with an acceptance limit. This document is what the provider manufactures against and what an acceptance dispute is settled by.
  3. Comparability between lots. Agree what evidence shows a new lot is equivalent to the last: the same release panel plus a side-by-side test in your own assay against a retained reference. Without a reference aliquot you have no way to distinguish a lot difference from an experimental one.
  4. Formulation, storage and shipping. The buffer, the concentration, the presence of carrier protein or stabiliser, and whether the material is frozen or lyophilised all affect how it behaves on arrival. Specify them, and require a temperature record with the shipment.
  5. Secure the inputs for the repeat. The cell bank, the construct and the process description are what make the second batch possible. Establish who holds them, where the backup is, and what your rights are before the first batch rather than after.

Where production differs from development

Development asks whether the protein can be made; production asks whether it can be made the same way again. Providers that excel at the first are not automatically good at the second, and the signals differ: for production, look at batch record discipline, deviation handling and how they describe changeover.

If the material will eventually support a regulated application, ask now what would have to change and what it would cost. Retrofitting a compliant process onto a research one is substantially more work than planning for it.

Keeping a reference

Retain aliquots from every lot in your own storage, under your own control. A retained reference is the only instrument you have for answering whether a change in results came from a new lot or from something else, and it costs almost nothing.

Record which lot produced which data. Laboratories that cannot map results to lots cannot investigate a lot problem at all, which is how a supplier change becomes an unexplained drift in a dataset.

gst tag protein purification, and when the tag suits

A glutathione S-transferase tag is large, it is expressed well in bacteria, it improves solubility for many partners, and it purifies on immobilised glutathione with a gentle elution. That combination suits a difficult soluble protein and a pull-down experiment. The costs are that GST dimerises, which changes the behaviour of anything that signals by clustering, that a 26 kilodalton tag has to be cleaved for most structural and functional work, and that the protease site adds a step and a second purification. Decide cleavage before cloning, not after.

cell free protein production, and where it fits

A cell free system transcribes and translates from a DNA or RNA template in a lysate or a reconstituted mixture, which removes the cell and therefore the growth, the toxicity limits and the days. It fits toxic proteins, unnatural amino acid incorporation, membrane proteins made into nanodiscs, rapid variant screening and anything needed in hours at microgram to low milligram scale. The costs are per milligram, well above fermentation, and the yield depends on the template's own design, so the promoter, the untranslated regions and the codon usage are part of the order.

A gip peptide order and the form that matters

A gip peptide order has to name the species, the residue range and whether the peptide is the active or the truncated form, since the hormone is cleaved rapidly by a surface protease and the fragment is inactive. Purity, counter-ion and water content decide what is weighed out, and an activity figure needs the assay it came from.

human epo as a recombinant protein order

An order for human epo is a specification rather than a name: expression host, glycosylation, carrier free status, endotoxin limit and specific activity in a named assay, because the sugar chains rather than the sequence carry much of the in vivo activity. A cell culture grade preparation and a reference standard are different products with different documentation.

his tag beads and what the resin decides

his tag beads are metal charged particles, and the metal decides the balance between yield and purity: nickel binds more and brings more contaminants, cobalt is cleaner and lower yielding. Magnetic beads suit small samples and automation while a column suits volume. Reducing agents and chelators in the lysate strip the metal, which is the commonest reason a purification fails entirely.

Common questions

How large a batch of custom proteins should I order?
Enough for consumption within the material's demonstrated stability period plus a reserve. A larger batch at a better unit price is a false economy if the protein degrades before it is used.
What should a release specification contain?
Identity, purity and concentration each by a stated method, activity where relevant, aggregate, endotoxin where the material touches cells, and appearance, each with an acceptance limit agreed before manufacture.
How do I know a new lot matches the old one?
The same release panel, plus a side-by-side comparison against a retained aliquot of the previous lot in your own assay. Without a retained reference the comparison cannot be made.
What do I need to secure repeat supply?
Access to the cell bank, the construct and a written process description, with a backup held somewhere other than the provider's freezer. Settle this before the first batch.

Get a shortlist for your project

Free. We send a shortlist of vendors whose published prices and service scope fit what you described, built from the verified index on this site. We may email you about this enquiry and similar services from this site; opt out any time, including from the first message.

Browse by service class

Sources

Cite or embed this figure

The median advertised gene synthesis price per base pair in the US research synthesis services market was $0.11 in August 2026, across 4 verified vendor service pages recorded in BioBricks Synthesis Price Index.

Cite as: "BioBricks Synthesis Price Index", updated 2026-08-24, https://biobricks.org/custom-protein-production/.

Embed this figure (plain HTML, no scripts)
median advertised gene synthesis price per base pair · the US research synthesis services market · August 2026

$0.11

Middle 50%$0.07 – $0.15
verified vendor service pages4

Source: BioBricks Synthesis Price Index

Get a vendor shortlistCompare synthesis prices